Literature DB >> 2244284

Carotid endarterectomy for chronic retinal ischemia.

J R Rubin1, K M McIntyre, M C Lukens, E J Plecha, V M Bernhard.   

Abstract

Carotid arterial disease may result in a variety of ischemic ocular problems that can eventually lead to permanent blindness. From 1984 to 1988, 18 patients underwent reconstruction of the carotid artery in an attempt to restore normal retinal arterial flow and, thereby, reverse or prevent progression of ischemic oculopathy. During a mean period of 21 months after carotid arterial reconstruction, subjective improvement in vision as well as a resolution in eye and periorbital pain was reported in 87.5 per cent of the patients. Measured visual acuity improved or stabilized in 94.4 per cent; macular photostress recovery times improved in 87.5 per cent, funduscopic examinations noted improvement or resolution in ischemic signs in 93.3 per cent and intraocular pressures improved in two of three patients. One patient experienced recurrent episodes of amaurosis fugax, which resolved after two weeks and did not recur. A second patient experienced an increase in intraocular pressures with visual deterioration, required laser photocoagulation after which the condition of the patient stabilized but only after significant visual impairment. Carotid arterial reconstruction is effective for the treatment of ischemic oculopathy and is most beneficial if performed early, before the onset of irreversible neovascular glaucoma.

Entities:  

Mesh:

Year:  1990        PMID: 2244284

Source DB:  PubMed          Journal:  Surg Gynecol Obstet        ISSN: 0039-6087


  2 in total

1.  Visual outcomes after carotid reconstructive surgery for ocular ischemia.

Authors:  V V Neroev; T N Kiseleva; S K Vlasov; N V Pak; A V Gavrilenko; A V Kuklin
Journal:  Eye (Lond)       Date:  2012-07-06       Impact factor: 3.775

2.  Carotid Artery Endarterectomy Effect on Choroidal Thickness: One-Year Follow-Up.

Authors:  Gilad Rabina; Dana Barequet; Michael Mimouni; Yefim Rabinovitch; Yehuda Wolf; Adiel Barak; Anat Loewenstein; Shulamit Schwartz
Journal:  J Ophthalmol       Date:  2018-12-18       Impact factor: 1.909

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.